BiotechTube
Home/Silence Therapeutics/Craig Tooman
CT

Craig Tooman

President and Chief Executive Officer

Silence Therapeutics

Therapeutic Areas

CardiovascularMetabolicHematologic

Silence Therapeutics Pipeline

DrugIndicationPhase
Zerlasiran (SLN360)Elevated Lipoprotein(a) for Cardiovascular Risk ReductionPhase 2
SLN124Iron-Refractory Iron Deficiency Anemia (IRIDA)Phase 2

Leadership Team at Silence Therapeutics

DD
Dr. David Horn Solomon
Chief Financial Officer
DK
Dr. Kishor M. Wasan
Chief Medical Officer
DR
Dr. Ralf Rosskamp
Chief Scientific Officer
DM
Dr. Michael G. Attenborough
Chief Business Officer
DI
Dr. Iain Ross
Chairman of the Board
View full Silence Therapeutics profile